Medaglini D Siegrist CA 2017 The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature. https://sonar.ch/global/documents/46696 eng info:eu-repo/semantics/altIdentifier/doi/10.1016/j.coviro.2017.03.008 info:eu-repo/semantics/altIdentifier/pmid/28460340 Current opinion in virology. - 2017 Drug Carriers Ebola Vaccines Ebolavirus Gene Expression Profiling Hemorrhagic Fever, Ebola Humans Immunoassay Metabolome Vaccines, Synthetic Vesiculovirus Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine. http://purl.org/coar/resource_type/c_6501